Bleeding risk in patients with atrial fibrillation: the AMADEUS study

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Atrial fibrillation (AF) management requires balancing stroke prevention with bleeding risk.
• Combination antithrombotic therapy, involving anticoagulants and antiplatelets, is sometimes used in AF patients.
• The comparative safety and efficacy of this approach versus anticoagulation alone need thorough investigation.

Purpose of the Study:

• To evaluate the impact of combination antithrombotic therapy on stroke and bleeding risks in AF patients.
• To compare these outcomes against anticoagulation therapy administered alone.

Main Methods:

• A post hoc analysis of 4,576 AF patients from the AMADEUS trial was conducted.
• Patients received either idraparinux or dose-adjusted vitamin K antagonists (VKAs).
• A subgroup (18.5%) received additional antiplatelet therapy, constituting combination antithrombotic therapy.

Main Results:

• Combination antithrombotic therapy was associated with a 2.3- to 2.5-fold increased risk of clinically relevant and major bleeding events.
• Age (65-74 and ≥75 years) also significantly increased bleeding risk.
• No significant reduction in ischemic stroke risk was observed with combination therapy compared to anticoagulation alone.

Conclusions:

• Combination antithrombotic therapy in AF patients elevates the risk of clinically relevant and major bleeding.
• This therapeutic strategy does not demonstrate a reduction in stroke risk.
• Careful consideration of the increased bleeding risk is warranted when prescribing combination antithrombotic therapy for AF.